Suffering

Adisi Health Center is Proudly Announcing the Launch of Its New Website and Plans of Expanding the Practice

Retrieved on: 
Tuesday, April 6, 2021

The welcoming environment of the practice provides a non-clinical touch, allowing patients to receive quality care in a comfortable and home-like atmosphere.

Key Points: 
  • The welcoming environment of the practice provides a non-clinical touch, allowing patients to receive quality care in a comfortable and home-like atmosphere.
  • The customized approach to each patient is enhanced by the state-of-the-art equipment, which complements the professional, top-rated care provided by Adisi's experts.
  • According to the American Pain Foundation, neck pain is the third most common type of pain affecting millions of Americans daily.
  • Dr. Steve Petzel is a renowned chiropractor specializing in muscle and joint-related health conditions with a holistic approach to patient care.

Compassion's Creative Covid Response

Retrieved on: 
Wednesday, March 31, 2021

And in the midst of these challenging circumstances, the ministry responded creatively in three ways:

Key Points: 
  • And in the midst of these challenging circumstances, the ministry responded creatively in three ways:
    Compassion focused on relief.
  • Although Compassion wouldn't define itself as a relief organization, the ministry quickly addressed the urgent needs of children and families.
  • In a challenging, chaotic year, Compassion got creative.
  • Compassion International is a Christian child development organization working to release children from poverty in Jesus' name.

Pain response is now measurable with the release of the new SERIES-5 MyoVision

Retrieved on: 
Tuesday, March 23, 2021

The device simultaneously measures range of motion and the muscular guarding response during motion, providing a truly objective answer to the age-old question, "Are you really in pain?"

Key Points: 
  • The device simultaneously measures range of motion and the muscular guarding response during motion, providing a truly objective answer to the age-old question, "Are you really in pain?"
  • Abnormal muscle activation, known as muscle guarding, is the body's natural response to pain.
  • By documenting muscle guarding during motion, the SERIES-5 provides doctors, jurors, IMEs and patients with consistent objective outcomes.
  • It proves with clinical certainty if a patient is injured and in pain or if they are not.

Allied Files Provisional Patent for Psilocybin Therapeutic Invention Seeking Drug Indication for Mental Health Depression and Anxiety Applications

Retrieved on: 
Thursday, March 18, 2021

These two products together administered under a novel treatment regimen is intended to be tested through the Allied clinical trial infrastructure to seek a drug indication for general depression and anxiety.

Key Points: 
  • These two products together administered under a novel treatment regimen is intended to be tested through the Allied clinical trial infrastructure to seek a drug indication for general depression and anxiety.
  • The provisional patent submitted is entitled: COMPOSITIONS AND FORMULATIONS OF PSILOCYBIN AND CANNABINOIDS AND METHODS OF THEIR USE TOGETHER FOR TREATING MENTAL HEALTH DISORDERS AND IMPROVING MENTAL HEALTH.
  • The content contemplated in the provisional patent submission describes the real world pharmaceutical formulations that Allied intends to research via human clinical trials in order to seek a drug indication.
  • Currently, treatment options for mental health disorders consist generally of psychotherapy, pharmacotherapy, and direct brain intervention.

InventHelp Inventors Develop Device to Relieve Back Pain while Sitting (RHO-1130)

Retrieved on: 
Wednesday, March 17, 2021

The invention provides an effective way to help relieve pain in the lower or middle back.

Key Points: 
  • The invention provides an effective way to help relieve pain in the lower or middle back.
  • In doing so, it offers an alternative to traditional pain relievers and devices.
  • The invention features a compact design that is convenient and easy to use so it is ideal for individuals who suffer from back pain and other issues.
  • "Our design eliminates the hassle of using different pillows, belts or ointments to temporarily relieve pain."

nView Health Chosen to Participate in Landmark Study of Anxiety in Children

Retrieved on: 
Wednesday, March 10, 2021

PCAY, a large multisite randomized control trial, funded by Patient Center Outcomes Research Institute (PCORI) aims to study the effectiveness of evidence-based treatments for child and adolescent anxiety.

Key Points: 
  • PCAY, a large multisite randomized control trial, funded by Patient Center Outcomes Research Institute (PCORI) aims to study the effectiveness of evidence-based treatments for child and adolescent anxiety.
  • Anxiety disorders represent the most common mental health conditions.
  • Among its several products, nView Health provides digital, pediatric DSM-5 behavioral health screeners, diagnostic interview tools and follow-up trackers.
  • nView Health offers behavioral health technology that enables healthcare professionals, researchers, and educators to rapidly deliver the right diagnosis, resulting in the right treatment at the right time.

BetterLife Enters Research Agreement with Carleton University for TD-0148A Depression Studies

Retrieved on: 
Monday, March 8, 2021

VANCOUVER, March 08, 2021 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (BetterLife or the Company) (CSE: BETR /OTCQB: BETRF / FRA: NPAU ), an emerging biotech company focused on the development and commercialization of cutting-edge treatments in mental disorders and viral infections, announces it has entered into an agreement with University of Carleton University (Carleton) for TD-0148As research in preclinical models of depression.

Key Points: 
  • VANCOUVER, March 08, 2021 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (BetterLife or the Company) (CSE: BETR /OTCQB: BETRF / FRA: NPAU ), an emerging biotech company focused on the development and commercialization of cutting-edge treatments in mental disorders and viral infections, announces it has entered into an agreement with University of Carleton University (Carleton) for TD-0148As research in preclinical models of depression.
  • "TD-0148A is a potential novel new therapy to treat debilitating psychiatric disorders with high unmet need, such as treatment resistant severe depression and post-traumatic stress disorder.
  • As part of the research agreement, Dr. Argel Aguilar-Valles team will work with BetterLife to test TD-0148A in both in vitro and in vivo models that are established in their lab.
  • Carleton Neuroscience has an international reputation for research on stress and its effects on brain functioning and mental health.

MINDCURE Discovers Potential Opportunity for Ibogaine-Assisted Psychotherapy to Treat Neuropathic Pain and Traumatic Brain Injury

Retrieved on: 
Thursday, March 4, 2021

Recently, the Company's PsyCollage platform has identified the opportunity for the use of ibogaine to address neuropathic pain and brain trauma.

Key Points: 
  • Recently, the Company's PsyCollage platform has identified the opportunity for the use of ibogaine to address neuropathic pain and brain trauma.
  • "PsyCollage ensures we are moving in the right direction in our mission to provide alternative and effective treatment options for psychological and physiological pain," said Kelsey Ramsden, President & CEO, MINDCURE.
  • "Ibogaine has centuries of therapeutic history reinforcing its potential to heal pain.
  • MINDCURE is focused on identifying and developing pathways and products that ease suffering, increase productivity, and enhance mental health.

Worldwide Industry for Pharmaceutical Treatments for Mental Health Disorders to 2025 - Snapshot of Products in Phase III Development for Selected Psychiatric Disorders

Retrieved on: 
Friday, February 26, 2021

DUBLIN, Feb. 26, 2021 /PRNewswire/ -- The "Pharmaceutical Treatments for Mental Health Disorders: Global Markets" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Feb. 26, 2021 /PRNewswire/ -- The "Pharmaceutical Treatments for Mental Health Disorders: Global Markets" report has been added to ResearchAndMarkets.com's offering.
  • This new report on the market for pharmaceutical treatments for mental health disorders provides a brief overview of the pharmaceutical markets, current and future treatments, as well as drug failure/withdrawals and barriers to entry.
  • Mental health disorders refer to a wide range of mental health disorders that affect mood, thinking and behavior.
  • Reasons for Doing This Study:
    The treatment of mental health disorders is complex and often involves pharmacological and behavioral interventions.

Emory University’s Compassion Center Announces Plans for Global 21-Day Compassion Challenge That Begins March 6, 2021

Retrieved on: 
Thursday, February 25, 2021

Emory Universitys Center for Contemplative Science and Compassion-Based Ethics, with the support of His Holiness The Dalai Lama, will kick off a 21-Day Compassion Challenge March 6, 2021.

Key Points: 
  • Emory Universitys Center for Contemplative Science and Compassion-Based Ethics, with the support of His Holiness The Dalai Lama, will kick off a 21-Day Compassion Challenge March 6, 2021.
  • The 21-Day Compassion Challenge is designed to help people recognize their capacity for compassion and learn how to practice it daily.
  • Over the course of three weeks, participants progress sequentially through a series of topics that explore the transformative power of compassion.
  • Cultivating compassion toward self and others is the urgent need of our time, said Lobsang Tenzin Negi, executive director of the Compassion Center.